The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease

Cancer Letters

Volumn 400, Issue , 2017, Pages 293-304

  Kerbel, Robert S ^a   Shaked, Yuval ^b  

^a Canada   (Canada)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Animal models; Antiangiogenesis; Immunotherapy; Metastasis; Metronomic chemotherapy; Vessel co option

Indexed keywords

FLUOROURACIL; GEMCITABINE; MONOCLONAL ANTIBODY DC101; PAZOPANIB; SORAFENIB; SUNITINIB; TOPOTECAN; UFT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER STEM CELL; CELLULAR IMMUNITY; EPITHELIAL MESENCHYMAL TRANSITION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; MAXIMUM TOLERATED DOSE; METASTASIS; METRONOMIC DRUG ADMINISTRATION; MULTIMODAL CHEMOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG SCREENING; MOUSE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014467407     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.02.005     Document Type: Review

References (70)

1. Kamb, A., What's wrong with our cancer models?. Nat. Rev. Drug Discov. 4:2 (2005), 161–165.
2. Francia, G., Cruz-Munoz, W., Man, S., Xu, P., Kerbel, R.S., Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer. 11 (2011), 135–141.
3. Amiri-Kordestani, L., Fojo, T., Why do phase III clinical trials in oncology fail so often?. J. Natl. Cancer Inst. 104:8 (2012), 568–569.
4. Grignolo, A., Pretorius, S., Phase III trial failures: costly, but preventable. Appl. Clin. Trials., 25(8), 2016.
5. Kerbel, R.S., Guerin, E., Francia, G., Xu, P., Lee, C.R., Ebos, J.M.L., et al. Evaluating outcomes of antiangiogenic and chemotherapy in preclinical mouse models mimicking postsurgical adjuvant or metastatic breast cancer therapy. Breast 22 (2013), S57–S65.
6. Ebos, J.M.L., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15 (2009), 232–239.
7. Wu, F.T., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C.R., et al. Efficacy of cotargeting Angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal, and renal cancers. Cancer Res. 76 (2016), 6988–7000.
8. Wu, F.T., Paez-Ribes, M., Xu, P., Man, S., Bogdanovic, E., Thurston, G., et al. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Sci. Rep., 6, 2016, 36694.
9. Paez-Ribes, M., Man, S., Xu, P., Kerbel, R.S., Development of patient derived xenograft models of overt spontaneous breast cancer metastasis: a cautionary note. PLoS One., 11(6), 2016, e0158034.
10. Kerbel, R.S., Paez-Ribes, M., Man, S., Xu, P., Guerin, E., Cruz-Munoz, W., et al. Modelling therapy of late or early stage metastatic disease in mice. Cancer Med., 2016 in press.
11. Rampetsreiter, P., Casanova, E., Eferi, R., Genetically modified mouse models of cancer invasion and metastasis. Drug Discov. Today Dis. Models. 9 (2011), 67–74.
12. Saxena, M., Christofori, G., Rebuilding cancer metastasis in the mouse. Mol. Oncol. 7:2 (2013), 283–296.
13. Cho, H., Herzka, T., Zheng, W., Qi, J., Wilkinson, J.E., Bradner, J.E., et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 4:3 (2014), 318–333.
14. Munoz, R., Man, S., Shaked, Y., Lee, C., Wong, J., Francia, G., et al. Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66 (2006), 3386–3391.
15. Hackl, C., Man, S., Francia, G., Xu, P., Kerbel, R.S., Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62 (2013), 259–271.
16. Jedeszko, C., Paez-Ribes, M., Di Desidero, T., Bocci, G., Man, S., Lee, C.R., et al. Orthotopic primary and postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent anti-tumor activity of minimally toxic metronomic oral topotecan with pazopanib. Sci. Transl. Med., 7(282), 2015 282ra250.
17. Hashimoto, K., Man, S., Xu, P., Cruz-Munoz, W., Tang, T., Kumar, R., et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9 (2010), 996–1006.
18. Cruz-Munoz, W., Man, S., Xu, P., Kerbel, R.S., Development of a preclinical model of spontaneous human melanoma CNS metastasis. Cancer Res. 68 (2008), 4500–4505.
19. Tang, T.C., Man, S., Lee, C.R., Xu, P., Kerbel, R.S., Impact of UFT/cyclophosphamide metronomic chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 12 (2010), 264–274.
20. Palmieri, D., Chambers, A.F., Felding-Habermann, B., Huang, S., Steeg, P.S., The biology of metastasis to a sanctuary site. Clin. Cancer Res. 13:6 (2007), 1656–1662.
21. Lin, N.U., Winer, E.P., Brain metastases: the HER2 paradigm. Clin. Cancer Res. 13:6 (2007), 1648–1655.
22. Guerin, E., Man, S., Xu, P., Kerbel, R.S., A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 73 (2013), 2743–2748.
23. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357:26 (2007), 2666–2676.
24. Bridgeman, V.L., Vermeulen, P.B., Foo, S., Bilecz, A., Kostaras, L., Daley, F., et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol., 2016, 10.1002/path.4845 epub ahead of print.
25. Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 14:10 (2013), 933–942.
26. Paez-Ribes, M., Man, S., Xu, P., Kerbel, R.S., Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin. Cancer Res. 21 (2015), 5488–5498.
27. Bear, H.D., Tang, G., Rastogi, P., Geyer, C.E. Jr., Liu, Q., Robidoux, A., et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 16:9 (2015), 1037–1048.
28. Pezzella, F., Di, B.A., Andreola, S., Nicholson, A.G., Pastorino, U., Harris, A.L., Angiogenesis in primary lung cancer and lung secondaries. Eur. J. Cancer. 32A:14 (1996), 2494–2500.
29. Donnem, T., Hu, J., Ferguson, M., Adighibe, O., Snell, C., Harris, A.L., et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?. Cancer Med. 2:4 (2013), 427–436.
30. Vermeulen, P.B., Colpaert, C., Salgado, R., Royers, R., Hellemans, H., Van den Heuvel, E., et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 195:3 (2001), 336–342.
31. Kuczynski, E.A., Yin, M., Bar-Zion, A., Lee, C.R., Butz, H., Man, S., et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl. Cancer Inst., 108(8), 2016.
32. Frentzas, S., Bridgeman, V.L., Simoneau, E., Vermeulen, P.B., Foo, S., Wotherspoon, A., et al. Vessel co-option mediates resistance to antiangiogenic therapy in liver metastases. Nat. Med. 22:11 (2016), 1294–1302.
33. Browder, T., Butterfield, C.E., Kraling, B.M., Marshall, B., O'Reilly, M.S., Folkman, J., Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000), 1878–1886.
34. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000), R15–R24.
35. Pasquier, E., Kavallaris, M., Andre, N., Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7:8 (2010), 455–465.
36. Kerbel, R.S., Kamen, B.A., Antiangiogenic basis of low-dose metronomic chemotherapy. Nat. Rev. Cancer. 4 (2004), 423–436.
37. Fidler, I.J., Ellis, L.M., Chemotherapeutic drugs–more really is not better. Nat. Med. 6:5 (2000), 500–502.
38. Cruz-Munoz, W., Man, S., Kerbel, R.S., Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin. Cancer Res. 15:15 (2009), 4867–4874.
39. Pietras, K., Hanahan, D., A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23:5 (2005), 939–952.
40. Colleoni, M., Gray, K.P., Gelber, S., Lang, I., Thurlimann, B., Gianni, L., et al. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: international breast cancer study group trial 22-00. J. Clin. Oncol. 34:28 (2016), 3400–3408.
41. Simkens, L.H.J., van Tinteren, H., May, A., Ten Tije, A.J., Creemers, G.-J.M., Loosveld, O.J.L., et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer, the phase 3 CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). Lancet 385 (2015), 1843–1852.
42. Shaked, Y., Emmenegger, U., Francia, G., Chen, L., Lee, C.R., Man, S., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 65:16 (2005), 7045–7051.
43. Zagozdzon, R., Golab, J., Immunomodulation by anticancer chemotherapy: more is not always better (review). Int. J. Oncol. 18:2 (2001), 417–424.
44. Hermans, I.F., Chong, T.W., Palmowski, M.J., Harris, A.L., Cerundolo, V., Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 63:23 (2003), 8408–8413.
45. Noguchi, M., Moriya, F., Koga, N., Matsueda, S., Sasada, T., Yamada, A., et al. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol. Immunother. 65:2 (2016), 151–160.
46. Tagliamonte, M., Petrizzo, A., Napolitano, M., Luciano, A., Arra, C., Maiolino, P., et al. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol. Immunother. 64:10 (2015), 1305–1314.
47. Chen, C.A., Ho, C.M., Chang, M.C., Sun, W.Z., Chen, Y.L., Chiang, Y.C., et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 18:6 (2010), 1233–1243.
48. Parra, K., Valenzuela, P., Lerma, N., Gallegos, A., Reza, L.C., Rodriguez, G., et al. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br. J. Cancer. 116:3 (2017), 324–334.
49. Wu, J., Jordan, M., Waxman, D.J., Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. BMC Cancer., 16, 2016, 623.
50. Doloff, J.C., Waxman, D.J., VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 72:5 (2012), 1103–1115.
51. Wu, J., Waxman, D.J., Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett. 353:2 (2014), 272–280.
52. Kaneno, R., Shurin, G.V., Tourkova, I.L., Shurin, M.R., Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med., 7, 2009, 58.
53. Hasnis, E., Alishekevitz, D., Gingis-Veltski, S., Bril, R., Fremder, E., Voloshin, T., et al. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia 16:6 (2014), 501–510.
54. Shaked, Y., Pham, E., Hariharan, S., Magidey, K., Beyar-Katz, O., Xu, P., et al. Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy. Cancer Res. 76:20 (2016), 5983–5993.
55. Burton, J.H., Mitchell, L., Thamm, D.H., Dow, S.W., Biller, B.J., Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J. Vet. Intern Med. 25:4 (2011), 920–926.
56. Banissi, C., Ghiringhelli, F., Chen, L., Carpentier, A.F., Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58:10 (2009), 1627–1634.
57. Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61:3 (2012), 353–362.
58. Wan, S., Pestka, S., Jubin, R.G., Lyu, Y.L., Tsai, Y.C., Liu, L.F., Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One., 7(3), 2012, e32542.
59. Shaked, Y., Tang, T., Woloszynek, J., Daenen, L., Man, S., Xu, P., et al. Contribution of G-CSF to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 69 (2009), 7524–7528.
60. Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63 (2003), 4342–4346.
61. Shaked, Y., Kerbel, R.S., Antiangiogenic strategies on defense: blocking rebound by the tumor vasculature after chemotherapy. Cancer Res. 67 (2007), 7055–7058.
62. Daenen, L.G., Shaked, Y., Man, S., Xu, P., Voest, E.E., Hoffman, R.M., et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent anti-tumor activity in preclinical human tumor xenograft models. Mol. Cancer Ther. 8 (2009), 2872–2881.
63. Shaked, Y., Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat. Rev. Clin. Oncol. 13:10 (2016), 611–626.
64. Shree, T., Olson, O.C., Elie, B.T., Kester, J.C., Garfall, A.L., Simpson, K., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25:23 (2011), 2465–2479.
65. Alishekevitz, D., Gingis-Velitski, S., Kaidar-Person, O., Gutter-Kapon, L., Scherer, S.D., Raviv, Z., et al. Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3. Cell Rep. 17:5 (2016), 1344–1356.
66. Lotti, F., Jarrar, A.M., Pai, R.K., Hitomi, M., Lathia, J., Mace, A., et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 210:13 (2013), 2851–2872.
67. Chan, T.-S., Hsu, C.-C., Pai, V.C., Liao, W.-Y., Huang, S.-S., Tan, K.-T., et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J. Exp. Med. 213 (2016), 2967–2988.
68. Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, C.R., Zhu, Z., et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 69:18 (2009), 7243–7251.
69. Beck, B., Driessens, G., Goossens, S., Youssef, K.K., Kuchnio, A., Caauwe, A., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478:7369 (2011), 399–403.
70. Kerbel, R.S., Shaked, Y., Therapy-activated stromal cells can dictate tumor fate. J. Exp. Med. 213:13 (2016), 2831–2833.